The July issue of the Journal of the Neurological Sciences Vol 475 is now available online.
Issue highlights
Review Article
Intravenous thrombolysis for acute ischemic stroke patients with cerebral amyloid angiopathyChen et al.Published online: June 21, 2025
An explorative analysis of a nationwide database of hospitalizations in the United States. AIS patients with CAA were identified and included in the study, and cases were divided into IVT and no-IVT groups. Propensity score matching was performed to balance treatment groups, and additional multivariable logistic regressions were used for doubly robust analyses. Primary outcome was routine discharge to home with self-care. Secondary outcomes include discharge to home, in-hospital mortality, intracerebral hemorrhage (ICH), and subarachnoid hemorrhage (SAH). |
|
Research Article
The role of brain CT perfusion in acute ischemic stroke patients in the early time windowGentile et al.Published online: June 6, 2025
International guidelines recommend only non-contrast CT (NCCT) for eligible acute ischemic stroke (AIS) patients receiving intravenous thrombolysis (IVT) in the early time window. We aim to assess the potential role of advanced neuroimaging in predicting radiological and clinical outcomes in AIS patients treated with IVT within 4.5 h of stroke onset. |
|
Research Article
Effect of home-based telerehabilitation on motor function and health-related quality of life in stroke survivorsYokota et al.Published online: May 14, 2025
Home-based telerehabilitation (TR) for stroke survivors is expected to fill gaps in poststroke care for improvement of functional status. The aim was to examine the efficacy of the home-based TR for enhancing motor function and health-related quality of life (HRQOL) in stroke or transient ischemic attack (TIA) survivors 3 months after disease onset (3 M).
|
|
Research Article
Subjective cognitive function in individuals with multiple sclerosis: Associations with objective cognitive function, anxiety, depression, and fatigueGlanz et al.Published online: June 23, 2025
The authors conducted a prospective observational study that included patients who had a confirmed diagnosis of SPMS at the time of study entry and had been treated with fingolimod for at least two years. Upon enrollment, patients either continued fingolimod (comparator group) or transitioned to siponimod (switch group) and were followed up for six months to assess disease activity and changes in laboratory parameters. |
Web design by Tribal Systems